Viracta Therapeutics (NASDAQ:VIRX) PT Lowered to $4.00

Viracta Therapeutics (NASDAQ:VIRX) had its price objective trimmed by Royal Bank of Canada from $6.00 to $4.00 in a report issued on Thursday, Benzinga reports. The firm currently has an outperform rating on the stock.

Separately, Oppenheimer reduced their price objective on shares of Viracta Therapeutics from $13.00 to $11.00 and set an outperform rating for the company in a research report on Thursday, May 23rd.

Viracta Therapeutics Price Performance

VIRX opened at $0.31 on Thursday. Viracta Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.52. The company has a market capitalization of $12.08 million, a price-to-earnings ratio of -0.25 and a beta of 0.73. The firm’s fifty day moving average price is $0.52 and its two-hundred day moving average price is $0.72.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.